Arcturus Therapeutics (ARCT) Projected to Release Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) is expected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Arcturus Therapeutics to post earnings of ($1.07) per share and revenue of $3.1080 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Friday, May 8th. The biotechnology company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.08. The company had revenue of $2.06 million for the quarter, compared to analyst estimates of $6.30 million. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. On average, analysts expect Arcturus Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock traded up $0.02 during midday trading on Tuesday, reaching $6.02. 108,364 shares of the company’s stock traded hands, compared to its average volume of 467,451. Arcturus Therapeutics has a 52 week low of $5.50 and a 52 week high of $24.17. The company’s 50 day simple moving average is $6.87 and its 200 day simple moving average is $7.41. The company has a market cap of $171.11 million, a price-to-earnings ratio of -2.14 and a beta of 2.37.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ARCT. Osaic Holdings Inc. raised its stake in Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 738 shares during the last quarter. BNP Paribas Financial Markets grew its position in Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in Arcturus Therapeutics by 27.5% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,567 shares during the last quarter. Strs Ohio bought a new position in shares of Arcturus Therapeutics during the 1st quarter worth about $89,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Arcturus Therapeutics during the fourth quarter valued at about $64,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ARCT. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut Arcturus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $24.25.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.